NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 56 filers reported holding NEUROCRINE BIOSCIENCES INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,587 | -100.0% | 1,000 | -100.0% | 0.00% | -100.0% |
| Q4 2020 | $64,681,000 | -0.6% | 46,390,000 | 0.0% | 0.06% | -15.8% |
| Q3 2020 | $65,053,000 | -38.2% | 46,390,000 | -23.2% | 0.08% | -37.7% |
| Q2 2020 | $105,347,000 | +23.9% | 60,425,000 | -5.5% | 0.12% | +7.0% |
| Q1 2020 | $85,025,000 | -24.2% | 63,975,000 | -11.4% | 0.11% | +10.7% |
| Q4 2019 | $112,242,000 | +22.7% | 72,175,000 | +8.4% | 0.10% | +14.4% |
| Q3 2019 | $91,443,000 | +28.3% | 66,555,000 | +23.5% | 0.09% | +36.4% |
| Q2 2019 | $71,274,000 | -12.7% | 53,905,000 | -12.3% | 0.07% | -18.5% |
| Q1 2019 | $81,630,000 | +5.0% | 61,500,000 | -5.6% | 0.08% | -4.7% |
| Q4 2018 | $77,766,000 | -39.9% | 65,145,000 | -13.5% | 0.08% | -27.4% |
| Q3 2018 | $129,343,000 | +6.0% | 75,285,000 | -10.2% | 0.12% | -1.7% |
| Q2 2018 | $122,059,000 | – | 83,875,000 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TENOR CAPITAL MANAGEMENT Co., L.P. | 45,447,000 | $60,497,000 | 1.31% |
| SHENKMAN CAPITAL MANAGEMENT INC | 4,366,000 | $5,924,000 | 0.54% |
| Aequim Alternative Investments LP | 7,609,000 | $10,088,000 | 0.43% |
| MACKAY SHIELDS LLC | 27,806,000 | $37,405,000 | 0.35% |
| Weiss Asset Management LP | 10,000,000 | $13,290,000 | 0.33% |
| WOLVERINE ASSET MANAGEMENT LLC | 13,230,000 | $17,541,000 | 0.13% |
| Polar Asset Management Partners Inc. | 7,500,000 | $9,942,000 | 0.10% |
| LORD, ABBETT & CO. LLC | 22,141,000 | $29,732,000 | 0.07% |
| Calamos Advisors LLC | 7,500,000 | $9,967,000 | 0.05% |
| D. E. Shaw & Co., Inc. | 39,270,000 | $52,046,000 | 0.04% |